ARDX vs AUPH
ARDX: Ardelyx commercializes tenapanor-based therapies (IBSRELA for IBS-C, XPHOZAH for kidney disease hyperphosphatemia) with a pipeline of next-generation NHE3 inhibitors. AUPH: Aurinia is a specialty pharma company commercializing LUPKYNIS, the first oral calcineurin inhibitor approved for lupus nephritis, with strong profitability and cash generation funding pipeline expansion.
Side-by-side fundamentals
| Metric | ARDX | AUPH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.08 | $15.33 | |
| Market cap as of 2026-07-23 | $1.3B | $2.0B | |
| P/E as of 2026-07-23 | n/a | 6.63 | |
| PEG as of 2026-07-23 | -4.33 | 0.01 | ARDX lower |
| Net margin as of 2026-07-23 | -13.6% | +100.0% | AUPH higher |
| Gross margin as of 2026-07-23 | +92.5% | +89.7% | ARDX higher |
| Operating margin as of 2026-07-23 | -8.8% | +41.7% | AUPH higher |
| ROE as of 2026-07-23 | -38.1% | +64.5% | AUPH higher |
| ROA as of 2026-07-23 | -11.8% | +47.6% | AUPH higher |
| Debt / equity as of 2026-07-23 | 1.37 | 0.11 | AUPH lower |
| Revenue growth (YoY) as of 2026-07-23 | +18.2% | +20.6% | AUPH higher |
| Revenue CAGR (3y) SEC XBRL | +98.4% | +28.3% | ARDX higher |
| Beta as of 2026-07-23 | 0.70 | 1.40 | |
| 1-year return as of 2026-07-22 close | +15.2% | +81.4% | AUPH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.